Transthyretin amyloidosis cardiomyopathy in patients with HFpEF in Russia

Trial Identifier: D8450R00006
Sponsor: AstraZeneca
Start Date: December 2023
Primary Completion Date: November 2024
Study Completion Date: November 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Akhtubinsk, Russia
Russia Astrakhan, Russia
Russia Beslan, Russia
Russia Izhevsk, Russia
Russia Kaluga, Russia
Russia Krasnodar, Russia
Russia Rostov-on-Don, Russia
Russia Smolensk, Russia
Russia Vladimir, Russia
Russia Vladivostok, Russia
Russia Volgograd, Russia
Russia Yaroslavl, Russia